Use

Mutations in the PDGFRA gene are found in a subset of gastrointestinal stromal tumors (GISTs), particularly in KIT wild‑type tumors. These mutations can drive ligand‑independent auto‑activation of the receptor, making affected tumors candidates for tyrosine kinase inhibitor therapy. Notably, the PDGFRA D842V mutation is a common variant in exon 18 associated with resistance to imatinib but responsiveness to avapritinib (AYVAKIT), making identification of this mutation clinically actionable. ([jdos.nicholsinstitute.com](https://jdos.nicholsinstitute.com/dos/fmh/test/595983?utm_source=openai))

Not provided.